Point Biopharma deal reads positively to radiopharma names, says B. Riley

B. Riley says Eli Lilly’s (LLY) deal to acquire Point Biopharma (PNT) validates the value of late-stage radiopharmaceuticals assets. The acquisitions shows Lilly’s strategic interest in targeted radiotherapeutics, especially alpha emitters, which reads positively to radiopharma names Actinium Pharmaceuticals (ATNM), Fusion Pharmaceuticals (FUSN), and Lantheus (LNTH), the analyst tells investors in a research note.